Post-radiation sinusitis is associated with recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy

Chih-Jen Huang1,2, Ming-Yii Huang1,2, Ming-Chen Paul Shih3,4, Kai-yuan Cheng5, Ka-Wo Lee5, Tzu-Ying Lu1,2, Shyng-Shiou Yuan6 and Pen-Tzu Fang1,2*

Abstract

Background: This study investigated the impact of post-radiation sinusitis on the prognosis of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT).

Methods: Two hundred and thirty patients with non-metastatic NPC were analyzed in terms of freedom from local failure (FFLF), freedom from distant failure (FFDF), overall survival (OS), and disease-free survival (DFS). For each patient, the status of the sinus mucosa was flexibly assessed by documenting mucosal changes as indicated by differences between images obtained before radiotherapy and more than 6 months post-radiation.

Results: With a median follow-up of 39.7 months (8 to 81 months), 19 (8.26%) patients relapsed locally, 13 (5.65%) patients failed in the neck, and 26 (11.3%) patients developed distant metastases. The presence of sinusitis noted in images post-radiation was a significant predictor for DFS ($p = 0.001$), FFLF ($p = 0.004$), and FFDF ($p = 0.015$), in addition to having high negative predictive value for local relapse (97.5%).

Conclusions: This is the first study to investigate the prognostic value of post-radiation sinusitis in NPC patients treated with IMRT. Post-radiation sinusitis was found to be a significant predictor for DFS, FFLF, and FFDF, and was also found to have high negative predictive value for local recurrence (97.5%). It may thus be used as an additional tool for clinicians to determine the possibility of recurrence.

Keywords: Nasopharyngeal carcinoma, Intensity-modulated radiation therapy, Post-radiation sinusitis, Recurrence

Background

Nasopharyngeal carcinoma (NPC) is a common cancer in Taiwan and Southeast Asia. For early stage NPC, the standard treatment is radiotherapy (RT) alone. For the advanced stage of the disease, a combination of chemotherapy and RT is necessary [1]. Due to advances in RT techniques, improvements in treatment outcomes have been achieved. In the past decade, intensity-modulated radiotherapy (IMRT) has been proven to be a more effective means of treating NPC than conventional RT [2, 3]. This breakthrough technique allows dose escalation to the tumor and delivers a highly conformal dose distribution in treating NPC. Therapeutic gains have been achieved by simultaneously improving local control and reducing RT-related toxicity.

Clinicians are making ongoing efforts to discover useful prognostic factors in this new IMRT era, given that IMRT has already been shown to have different dosimetric characteristics than three-dimensional conformal radiation therapy (3D-CRT). Some researchers have analyzed the patterns of local and regional failure [4–6], while others have sought to identify different predictors for local recurrence [7–10]. For local recurrence, the T stage is still the most well recognized prognostic factor,
while tumor volume is a somewhat controversial predictor of local recurrence and cutoff volume is still being investigated with regard to its predictive value [8, 9, 11, 12]. Most authors agree that distant metastasis continues to pose the most difficult treatment challenge despite the use of combined chemotherapy. After treatment, Epstein-Barr virus (EBV) DNA is helpful for surveillance [13–15]; however, the quantitative methods used in each laboratory are different, and the interpretation criteria vary for every facility. So, practitioners are making efforts to investigate new available and useful prognostic factors for the purposes of surveillance after treatment.

This study sought to investigate the prognostic factors of NPC patients treated with IMRT and was approved by the institutional review board at Kaohsiung Medical University Hospital.

**Methods**

**Patient characteristics**

Between November 2007 and June 2013, 230 histologically diagnosed non-metastatic NPC patients were treated with IMRT at Kaohsiung Medical University Hospital in Kaohsiung, Taiwan. For each patient, various pretreatment evaluations were conducted, including a history and physical examination, dental evaluation, blood test, nasoendoscopy, computed tomography (CT) or magnetic resonance imaging (MRI) of the head and neck, chest X-ray, bone scan, and abdominal sonography or positron emission tomography (PET). Tumors were staged according to the 2010 American Joint Committee on Cancer (AJCC) staging classifications [16]. Histologic classifications were made according to the 2005 World Health Organization (WHO) pathologic classification [17].

**Radiotherapy**

IMRT was delivered via either helical tomotherapy (HT; Accuray Incorporated, Sunnyvale, CA) or volumetric modulated arc therapy (VMAT; RapidArc, Varian Medical Systems, Palo Alto, CA). Patients were immobilized in a supine position with a thermoplastic mask covering the head and neck. A CT simulation with a slice thickness of 3 mm was performed, and target and normal structures were delineated on a Pinnacle treatment planning system (Phillips Healthcare, The Netherlands). The gross tumor volume (GTV) included the macroscopic primary tumor and involved lymph nodes of more than 10 mm in diameter. The clinical target volume high (CTVhigh) included the GTV with an expansion of 3 mm. The CTVmid was designed to include areas at risk for microscopic involvement, including the entire nasopharynx, the retropharyngeal nodal regions, the skull base, the clivus, the pterygoid fossa, the parapharyngeal space, the sphenoid sinus, the posterior third of the nasal cavity/maxillary sinuses and the pterygopalatine fossa, and lymph nodes at levels II–III, level VA, and the retropharyngeal space (ipsilateral level IB was included if the N stage was positive). Level IV and level VB were included in the CTVlow. The planning target volume (PTV) was defined as the CTV with 3-mm margins in all dimensions. However, in areas in which the CTV was adjacent to critical normal structures (e.g., the brainstem), the margin was reduced to 1 mm. The prescribed doses for PTVhigh, PTVmid, and PTVlow were 69.96-70Gy in 33–35 fractions, 59.4–63Gy in 33–35 fractions, and 54.45-56Gy in 33–35 fractions, respectively. The organs at risk (OAR) (i.e., the brainstem, spinal cord, lenses, eyes, optic nerves, chiasm, mandible, parotid glands, oral cavity, and throat) were contoured, and dose limitations were set modified based on the radiation therapy oncology group (RTOG) 0225 trial [18]. During treatment, kilovoltage cone beam CT (CBCT) image guidance for VMAT or megavoltage CT (MVCT) image guidance for HT was utilized to verify the tumor position.

**Chemotherapy**

For stage II–IVB patients, combined chemotherapy was needed and was provided based on the clinician’s assessment, with the factors considered including the patient’s age, The Eastern Cooperative Oncology Group (ECOG) scale of performance status, co-morbidities, tumor extent, and the patient’s own preferences. Neoadjuvant chemotherapy (NACT) followed by RT, concurrent chemo-RT (CCRT), and neoadjuvant chemotherapy followed by concurrent chemo-RT (NACCRT) were all accepted treatment options. For patients receiving NACT, the chemotherapy was administered as 2–3 cycles of cisplatin 70 mg/m² on day 1 and 5-fluorouracil 500–1000 mg/m² on days 2–5, every 3 weeks. For patients receiving CCRT, 2–3 cycles of cisplatin 70 mg/m² were delivered at 3-week intervals, or 6–7 cycles of cisplatin 30 mg/m² were delivered weekly. Two patients received concurrent cetuximab with radiotherapy.

**Follow-up**

After completion of the treatment, routine follow-ups were conducted every 3 months during the first 3 years, and then every 6 months thereafter. These follow-up evaluations consisted of a physical examination, nasoendoscopy, CT or MRI scan, chest X-ray, and abdominal sonography. Late toxicities were recorded in medical documents during follow up. Sinusitis was defined radiologically via CT scan or MRI scan [19–21]. The diagnosis criteria were as follows: enhanced scan showing fluid accumulation or opacification in the paranasal sinuses, or thickened sinus mucosa with trapped secretion, effusion, or air/fluid in the sinus cavity. Pre-radiation sinusitis was defined according to the imaging performed at the
time of diagnosis, while post-radiation sinusitis was defined according to the imaging performed more than 6 months after the radiotherapy. Massive improvement from pre-radiation sinusitis was also regarded as negative post-radiation sinusitis. The occurrence of sinusitis was determined by CJH, MCPS and PTF.

**Statistical analysis**

The statistical analysis was performed using SPSS 19.0 software. Several endpoints were evaluated: overall survival (OS), disease-free survival (DFS), freedom from local failure (FFLF), and freedom from distant failure (FFDF). The determinations of local relapse and distant metastasis were made based on physical examinations or radiographic images or were proven by pathological reports. The durations of DFS, FFLF, and FFDF were calculated from the date of completion of the main treatment to the date of documented failure, death from any cause, or the date of the last follow-up. The duration of OS was measured from the date of the diagnosis until death or the date of the last visit. The Kaplan-Meier method was used to calculate the cumulative OS, DFS, FFLF, and FFDF. Different prognostic factors were analyzed using the log-rank test. Among the statistically significant factors identified by univariate analysis, strongly related factors with \( P < 0.01 \) were selected for multivariate analysis. The Cox proportional-hazards model was used for multivariate analysis. The ENTER method was used. \( P < 0.05 \) was considered significant.

**Results**

A total of 230 patients with non-metastasis NPC were treated with IMRT at Kaohsiung Medical University Hospital between November 2007 and June 2013. The median age of these patients was 48.5 years (range: 18–80 years). One hundred seventy-seven of the patients were male, and 53 of the patients were female. Eighty-seven percent of the patients were in a locally advanced stage (stages II–IVB). The patient and disease characteristics are summarized in Table 1. With a median follow-up of 39.7 months (range: 8.2–81 months), the 3-year OS, DFS, FFLF, and FFDF rates were 91.4, 80.3, 90.6, and 87.5%, respectively. Nineteen local failures, 26 distant failures, and 17 deaths were observed, while a total of 43 relapses were noted. Among patients who experienced local recurrences and distant metastases, 63% developed local failure within 2 years, and 76.9% developed distant metastasis within 2 years. For the patients with post-radiation sinusitus versus those without post-radiation sinusitis, the 3-year OS, DFS, FFLF, and FFDF rates were, respectively, 97.4% versus 84.4%(\( p = 0.008 \)), 92.1% versus 66.5% (\( p < 0.001 \)), 97.9% versus 81.7% (\( p < 0.001 \)), and 94.1% versus 79.8%(\( p < 0.001 \)) (Fig. 1). Figure 2 shows the changes of sinusitis for these two groups of patients, i.e., those with and without post-radiation sinusitis. Before radiotherapy, the incidence of sinusitis among all the patients was 54.3%. After treatment, the incidence was 47%. Among the 125 patients with pre-radiation sinusitis, the sinusitis of 34 (27.2%) was alleviated after radiotherapy. Among the 105 patients without pre-radiation sinusitis, however, 17 (16.2%) developed post-radiation sinusitis. Furthermore, among the 122 patients who did not have post-radiation sinusitis, only 3 (2.5%) presented with local recurrence, meaning that the negative predictive value of post-radiation sinusitis for local recurrence was 97.5%.

The impact of various prognostic factors on the clinical outcomes was examined by univariate analysis. Various

---

**Table 1** Patient and disease characteristics

| Patient and Disease Characteristics | No (%) |
|------------------------------------|--------|
| Age Median (range)                 | 48.5 (18–80) |
| Gender                             |        |
| Male                               | 177 (77) |
| Female                             | 53 (23)  |
| Histology                          |        |
| WHO type 1                         | 3 (1.3) |
| WHO type 2.1 undifferentiated      | 77 (33.6) |
| WHO type 2.2 differentiated         | 112 (48.7) |
| WHO type 2 NOS                      | 37 (16.1) |
| WHO type 3 basaloid                | 1 (0.4)  |
| AJCC 7th Stage                      |        |
| I/I/II/III/IV                      | 30 (13)/77 (33.5)/78 (33.9)/45 (19.6) |
| T stage                            |        |
| 1/2/3/4                            | 106 (46.1)/61 (26.5)/34 (14.8)/29 (12.6) |
| N stage                            |        |
| 0/1/2/3                            | 59 (25.7)/86 (37.4)/66 (28.4)/19 (8.3) |
| RT modality                        |        |
| HT                                 | 155 (67.4) |
| VMAT                               | 75 (32.6) |
| Treatment factors                  |        |
| RT alone                           | 38 (16.5) |
| NACT+RT/NACCRT                     | 169 (73.5) |
| CCRT                               | 23 (10)  |
| Sinusitis                          |        |
| Pre-radiation sinusitis            |        |
| No                                 | 105 (45.7) |
| Yes                                | 125 (54.3) |
| Post-radiation sinusitis           |        |
| No                                 | 123 (53)  |
| Yes                                | 107 (47)  |

**Abbreviations:** VMAT volumetric modulated arc therapy, HT helical tomotherapy, NACT neoadjuvant chemotherapy, NACCRT neoadjuvant chemotherapy followed by concurrent chemoradiotherapy, CCRT concurrent chemoradiotherapy
prognostic factors were evaluated, including age, gender, T stage, N stage, the use of chemotherapy, and sinusitis status. Univariate analysis using the log-rank test revealed that age > 40 years, male gender, T4 stage, N3 stage, and post-radiation sinusitis were significantly associated with poorer outcomes in terms of OS and DFS. T4 stage and post-radiation sinusitis, however, were the only prognostic factors associated with poor FFLF. For FFDF, meanwhile, male gender, T4 stage, N3 stage, and post-radiation sinusitis were the significant prognostic factors (Table 2).

Multivariate analysis using the Cox proportional-hazards model showed that N3 stage and T3 stage were significant prognostic factors for OS, while male gender, T4 stage, N3 stage, and post-radiation sinusitis were independent factors predicting recurrence. Furthermore, N3 stage and post-radiation sinusitis were shown to be independent factors predicting distant metastasis, while post-radiation sinusitis and T stage were the independent factors predicting local recurrence. Table 3 depicts the significant prognostic factors of different end points according to the multivariate analysis.

**Discussion**

To our knowledge, this is the first study to have demonstrated a relationship between post-radiation sinusitis and local recurrence. Post-radiation sinusitis is not
uncommon after RT. In past studies, the incidence of post-radiation sinusitis was found to be highest at 3 to 6 months after RT, ranging from roughly 50 to 75% in NPC survivors following RT, and then gradually decreasing thereafter [21–23]. In those studies, sinusitis referred to radiological evidence of sinus mucosal change as opposed to any aspect of the clinical presentation. In the present study, the presence of post-radiation sinusitis more than 6 months after treatment was one of the prognostic factors indicating poor outcomes in terms of DFS, FFLF, and FFDF. Because post-radiation sinusitis tends to decrease and stabilize between six months and about a year after treatment, we documented the presence or absence of sinusitis during this period. Moreover, it was also reasonable to use post-radiation sinusitis at 6 months to 1 year after radiotherapy as a predictor given that most cases of recurrence occurred within 2 years in the present study. Thus, the presence of sinusitis documented 6 months after RT may be good cutoff time point for clinical practitioners seeking to predict local recurrence. Figure 2 shows changes in the sinuses from before to after RT in two patients. The images in Fig. 2a and b show a patient whose sinusitis was diminished post-RT and who then remained disease-free for 5 years. In contrast, the images in Fig. 2c and d depict another patient who developed bilateral maxillary sinusitis by 1 year post-RT and then experienced local recurrence as confirmed by biopsy.

The etiology of post-radiation sinusitis is assumed to be epithelial cell degeneration and ciliary dysfunction. Increased secretions and suppressed excretion function lead to the retention of secretions. Structural changes such as choanal atresia, hypertrophy of the turbinates, and nasal adhesion also worsen the condition [21, 22]. IMRT does not increase the incidence and severity of post-radiation sinusitis when compared to conventional 3D CRT [24]. With regard to the correlation between radiation field and post-radiation sinusitis, expert researchers have expressed conflicting opinions [21, 24].

There are two possible reasons that can explain the relationship between post-radiation sinusitis and local recurrence. One possible explanation is an association between the inflammatory process and carcinogenesis owing to high EBV infection prevalence rate among Chinese people. A retrospective cohort study based on the National Health Insurance database of Taiwan noted...
that those patients who presented with rhinosinusitis were found to have a 3.55-fold increased risk of developing NPC compared with individuals without rhinosinusitis [25]. The author of that study suggested that sinonasal EBV infections cause precancerization in NPC patients with certain genetic variations and that these infections then present as chronic rhinosinusitis. Moreover, such preexisting sinusitis will not worsen after RT, but rather will decrease [24]. Further studies of EBV DNA from biopsied sinus mucosal tissue may give us more clues in support of this theory. Another possible reason is the differing susceptibilities of the bony and mucosal structures of the paranasal sinuses to tumors or to radiation. In general, those patients who did not present with post-radiation sinusitis had a robust osteomeatal complex and a healthier environment, and were less likely to suffer from local tumor relapse. Meanwhile, better innate immunity and less inflammation among those who did not present with post-radiation sinusitis may have caused those patients to be less susceptible to tumor recurrence. That being said, a better understanding of the mechanisms involved in immunity and the inflammation process is needed to confirm or disprove these theories.

The correlation between T stage and the severity of post-radiation sinusitis has been discussed previously [21]. However, unlike other studies which investigated severity using Lund scores, in the present study, we focused only on the “presence” or “absence” of sinusitis, and found that the correlation between the presence of post-radiation sinusitis and T stage was weak (r = 0.303). We can also note that, according to the multivariate

### Table 2 Univariate analysis of prognostic factors

|                      | 3 yr. OS (%) | p     | 3 yr. DFS (%) | p     | 3 yr. FFLF (%) | p     | 3 yr. FFDF (%) | p     |
|----------------------|--------------|-------|---------------|-------|---------------|-------|---------------|-------|
| Gender               |              |       |               |       |               |       |               |       |
| Male                 | 89           | 0.025 | 76.3          | 0.009 | 89            | 0.06  | 84.9          | 0.018 |
| Female               | 100          | 0.009 | 94.4          | 0.009 | 96.3          | 0.06  | 96.8          | 0.018 |
| Age                  |              | 0.049 |               | 0.049 | 0.108         | 0.18  |               |       |
| < 40y/o              | 88.9         |       | 89.9          |       | 96.3          |       | 93.7          |       |
| > 40y/o              | 88.4         |       | 76.7          |       | 88.5          |       | 85.2          |       |
| T classification     |              | 0.002 | < 0.001       |       | < 0.001       |       | < 0.001       |       |
| T1–3                 | 94           |       | 84            |       | 93.8          |       | 89.4          |       |
| T4                   | 72.2         |       | 54.1          |       | 66.5          |       | 73.7          |       |
| N classification     |              | 0.001 | < 0.001       |       | < 0.001       |       | 0.654         |       |
| N0–2                 | 93.1         |       | 82.8          |       | 89.8          |       | 90.2          |       |
| N3                   | 71.6         |       | 51.7          |       | 88.9          |       | 57.4          |       |
| Chemotherapy         |              | 0.083 |               | 0.036 |               | 0.543 |               | 0.085 |
| No                   | 100          |       | 88.9          |       | 88.9          |       | 94.4          |       |
| Yes                  | 90           |       | 78.5          |       | 90.7          |       | 86.1          |       |
| Pre-radiation sinusitis |            | 0.048 |               | 0.002 |               | 0.057 |               | 0.082 |
| No                   | 96.4         |       | 89.4          |       | 93.7          |       | 91.4          |       |
| Yes                  | 87.1         |       | 72.5          |       | 87.9          |       | 84.2          |       |
| Post-radiation sinusitis |        | 0.008 | < 0.001       |       | < 0.001       |       | 0.003         |       |
| No                   | 97.4         |       | 92.1          |       | 97.9          |       | 94.1          |       |
| Yes                  | 84.4         |       | 66.5          |       | 81.7          |       | 79.8          |       |

**Abbreviations**: p p-value, OS overall survival rate, DFS disease-free survival rate, FFLF freedom from local failure, FFDF freedom from distant failure

### Table 3 Significant prognostic factors according to multivariate analysis

| End point                  | Hazard ratio (95%CI) | p-value |
|----------------------------|----------------------|---------|
| **Overall survival**       |                      |         |
| T stage T4 vs. T1–3        | 3.914 (1.441–10.63)  | 0.007   |
| N stage N3 vs. 0–2         | 4.735 (1.655–13.547) | 0.004   |
| **Disease-free survival**  |                      |         |
| Gender Male vs. Female     | 4.537 (1.392–14.792) | 0.012   |
| T stage T4 vs. T1–3        | 2.705 (1.359–5.384)  | 0.005   |
| N stage N3 vs. 0–2         | 3.425 (1.671–7.019)  | 0.001   |
| Post-radiation sinusitis Yes vs. no | 3.734 (1.732–8.051) | 0.001   |
| **Freedom from local failure** |                   |         |
| T stage T4 vs. T1–3        | 2.786 (1.069–7.259)  | 0.036   |
| Post-radiation sinusitis Yes vs. no | 8.9441 (2.002–39.965)| 0.004   |
| **Freedom from distant failure** |               |         |
| N stage N3 vs. 0–2         | 4.982 (2.149–11.552) | < 0.001 |
| Post-radiation sinusitis Yes vs. no | 2.951 (1.233–7.064) | 0.015   |
Conclusion

This study demonstrated that post-radiation sinusitis is one of the prognostic factors for poor DFS, FFLF, and FFDF, and that it has high negative predictive value for local recurrence. The reasons for this may be differing levels of patient immunity, the inflammatory process related to EBV infection, and structural abnormalities. This study still requires further validation.

Acknowledgements

The study was supported by grants from the Ministry of Health and Welfare (MOHW 106-TDU-B-212-144-007), Taiwan, Republic of China, and the Kaohsiung Medical University Hospital (KMUH 103-3-M41). The authors wish to express their gratitude for the assistance they received from the Statistical Analysis Laboratory, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University.

Funding

The study was supported by KMUH 103-3-M41 and MOHW 104-TDU-B-212-124-003.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

CCH and PTF conceived the study. CCH, MCPS and PTF carried out the determination of sinusitis. MYH participated in the design of the study. KYC and KWL helped to organize the study. TYL created the treatment plans and wrote part of the manuscript. SSY helped to draft the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the institutional review board at Kaohsiung Medical University Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Radiation Oncology, Kaohsiung Medical University Hospital, No.100, Tzyou 1st Road, Kaohsiung 807, Taiwan. 2Department of Radiation Oncology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 3Department of Medical imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 4Department of Radiology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 5Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 6Translational Research Center, Department of Otolaryngology-Head and Neck Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan.

Received: 3 January 2019 Accepted: 27 March 2019

Published online: 11 April 2019

References

1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310–7.
2. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53(1):12–22.
3. Cheng JC, Chao KS, Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer. 2001;96(2):316–21.
4. Kong F, Ying H, Du C, Huang S, Zhou J, Chen J, Sun L, Chen X, Hu C. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiat Oncol. 2014;9:60.
5. Li JX, Huang SM, Jiang XH, Ouyang B, Han F, Liu S, Wen BX, Lu TX. Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy. Radiat Oncol. 2014;9:87.
6. Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, Chen L, Zhou GQ, Li L, Ma J. Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chin J Cancer. 2012; 31(12):579–87.

7. Wang W, Feng M, Fan Z, Li J, Lang J. Clinical outcomes and prognostic factors of 695 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Biomed Res Int. 2014;2014(8):14948.

8. Guo R, Sun Y, Yu XL, Yin WJ, Li WF, Chen YY, Mao YP, Liu LZ, Li L, Lin AH, et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol. 2012; 104(3):294–9.

9. Wu Z, Zeng RF, Su Y, Gu MF, Huang SM. Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. Head Neck. 2013;35(5):680–94.

10. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, Wen BX, Wu YS, Mai HQ, Hong MH. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. Eur J Cancer. 2013;49(8):1023–31.

11. Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, et al. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol. 2011;29(34):4156–62.

12. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T. Long-term outcomes of intensity-modulated radiotherapy for 888 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiol Oncol. 2014;10(3):398–403.

13. Atta A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol. 2014;15(4):539–50.

14. Takiar V, Ma D, Garden AS, Li J, Rosenthal DI, Beadle BM, Frank SJ, Fuller CD, Gunn GB, Morrison WH, et al. Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy. Head Neck. 2015;38(1):33–9.

15. Tham MW, Lin S, Pan J, Han L, Lu JJ, Wee J. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer. Am J Clin Oncol. 2010;33(3):294–9.

16. Edge SB. American joint committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

17. Chan JBF, McCarron P, et al. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Lyon: IARC Press; 2005.

18. Lee N, Harris J, Garden AS, Straube W, Li J, Lu NY, Xiang YQ. Occurrence and the risk of nasopharyngeal cancer in a Taiwanese health study. Am J Epidemiol. 2010;73(2):163–72.

19. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242–9.

20. Lin JC, Jan JS, Chen KY, Hsu CY, Liang WM, Wang WY. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma. Head Neck. 2003;25(6):438–50.

21. Kam MK, Teo PM, Chau RM, Cheung KY, Chi PH, Kwan WH, Leung SF, Zee B, Chan AT. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2004;60(3):1440–50.

22. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, Lee AW. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;79(2):420–8.

23. Su SF, Han F, Zhao C, Huang Y, Chen CY, Xiao WW, Li JX, Lu TX. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chin J Cancer. 2011; 30(8):565–73.

24. Tham MW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET, Wee JT. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys. 2009;75(1):481–6.

25. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys. 2006; 64(1):57–62.

26. Huang CC, Huang SF, Lee TJ, Ng SH, Chang JT. Postradiation sinus mucosa disease in nasopharyngeal carcinoma patients. Laryngoscope. 2007;117(4): 737–42.

27. Yuan TZ, Guo X, Zheng L, Cao SM, Li NW, Xiang YQ. Occurrence and influencing factors of para nasal sinusitis in nasopharyngeal carcinoma patients after radiotherapy. Ai Zheng. 2008;27(8):866–9.

28. Bamberger DM. Antimicrobial treatment of sinusitis. Semin Respir Infect. 1991;6(2):77–84.

29. Hiin CH, Tseng HC, Lin HP, Chen TH. Sinus mucosa status in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy: a 5-year follow-up. Head Neck. 2014;36(8):ppp1.1(925-933).

30. Tsou YA, Lin CC, Tai CJ, Tsai MH, Tsai TC, Chen CM. Chronic rhinosinusitis and the risk of nasopharyngeal cancer in a Taiwanese health study. Am J Rhinol Allergy. 2014;28(4):168–72.

31. Teo PM, Ma BB, Chan AT. Radiotherapy for nasopharyngeal carcinoma—transition from two-dimensional to three-dimensional methods. Radiother Oncol. 2004;73(3):163–72.

32. Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN, Lui LT. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19(23):4305–13.